Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer

Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer

Summary: ARID1A, a subunit of the SWI/SNF complex, is among the most frequently mutated genes across cancer types. ARID1A is mutated in more than 50% of ovarian clear cell carcinomas (OCCCs), diseases that have no effective therapy. Here, we show that ARID1A mutation confers sensitivity to pan-HDAC...

Full description

Bibliographic Details
Main Authors: Takeshi Fukumoto, Pyoung Hwa Park, Shuai Wu, Nail Fatkhutdinov, Sergey Karakashev, Timothy Nacarelli, Andrew V. Kossenkov, David W. Speicher, Stephanie Jean, Lin Zhang, Tian-Li Wang, Ie-Ming Shih, Jose R. Conejo-Garcia, Benjamin G. Bitler, Rugang Zhang
Format: Article
Language:English
Published: Elsevier 2018-03-01
Series:Cell Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124718303486

Internet

http://www.sciencedirect.com/science/article/pii/S2211124718303486

Similar Items